Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data PharmaCyte Biotech, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Revenue
0
0
0
0
0
0
0
0
0
0
Research and development
1.18
2
0.46
0.3
0.92
0.69
0.47
0.41
0.44
0.39
General and administrative
0.74
1.82
1.38
1.16
0.42
1.09
1.11
6.11
3.94
4.91
Operating expenses
4.44
6.98
4.1
3.83
3.62
4.39
6.46
8.52
4.38
6.85
Operating income
-4.44
-6.98
-4.1
-3.83
-3.62
-4.39
-6.46
-8.52
-4.38
-6.85
Interest expense
0
0
0
0
0
0
0
Interest income
0
0.16
1.94
3.4
1.42
0.73
Other non-operating income
-0
0.15
0.03
-0
0.07
0.15
2.14
8.85
35
-12.6
Pre-tax income
30.7
-19.4
Income tax
0
0
0
0
0
0
0
0
0
0
Net income
-4.44
-6.83
-4.07
-3.83
-3.55
-4.24
-4.32
0.33
30.7
-19.4
EPS, basic
-0.01
-0.01
0.00
-4.23
-2.45
-0.27
-0.22
-1.80
3.19
-2.77
EPS, diluted
-0.01
-0.01
0.00
-4.23
-2.45
-0.27
-0.22
-1.80
3.19
-2.77
Shares, basic (weighted)
845
969
1,100
0.9
1.45
15.5
19.5
9.58
7.33
8.38
Shares, diluted (weighted)
845
969
1,100
0.9
1.45
15.5
19.5
9.58
7.33
8.38
Balance sheet
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
3.46
1.06
0.52
0.89
2.2
85.4
68
50.2
15.2
18.6
Short-term investments
0
0.37
0.25
Other current assets
0.07
0.22
0.14
0.14
0.07
0.09
0.11
0.26
0.22
0.1
Total current assets
3.54
1.28
0.65
1.04
2.28
85.5
68.1
50.4
22.4
37.4
Intangible assets
3.55
3.55
1.55
1.55
0
Other non-current assets
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Total assets
8.67
6.41
5.78
6.17
7.4
90.6
73.3
59.9
55.2
46.8
Accounts payable
0.37
0.35
0.12
0.19
0.17
0.21
0.13
0.39
0.4
0.27
Accrued liabilities
0.21
0.29
0.62
0.82
0.55
0.5
0.46
0.74
2.52
0.52
Total current liabilities
0.58
0.64
0.74
1.03
0.72
0.7
0.59
7.42
2.91
0.83
Total liabilities
0.58
0.64
0.74
1.08
0.72
0.7
0.59
20.4
3.28
11.8
Paid-in capital
97.1
102
105
109
114
202
202
185
181
183
Retained earnings
-89.1
-96
-100
-104
-107
-112
-116
-116
-85
-104
Treasury stock
0
-13.6
-42
-44.6
-45
Other comprehensive income
0
-0
-0.01
-0.02
-0.02
-0.02
-0.02
-0.02
-0.02
-0.02
Shareholders' equity
8.09
5.77
5.04
5.09
6.68
89.9
72.7
27.6
51.9
33.3
Total equity
8.09
5.77
5.04
5.09
6.68
89.9
72.7
27.6
51.9
33.3
Total liabilities and equity
8.67
6.41
5.78
6.17
7.4
90.6
73.3
59.9
55.2
46.8
Shares outstanding
905
1,013
1,186
1.09
1.59
20.7
16.8
8.04
6.8
10.7
Cash flow statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
-4.44
-6.83
-4.07
-3.83
-3.55
-4.24
-4.32
0.33
30.7
-19.4
Stock-based compensation
0.42
0.58
0.29
0.37
0.19
0.03
0.01
0.67
0
0.89
Change in payables
0.03
-0.01
-0.23
0.06
-0.01
0.03
-0.24
Cash from operations
-3.34
-5.08
-2.88
-2.34
-3.33
-4.12
-3.79
-2.15
-2.98
-5.15
Purchases of investments
0
-7
Cash from investing
0
0
0
0
0
0
0
-5
-7
2
Stock issued
4.88
2.68
2.34
2.66
4.7
87.4
0
Share buybacks
0
-13.6
-28.2
-2.54
-0.4
Cash from financing
4.88
2.68
2.34
2.73
4.64
87.3
-13.6
-10.7
-25
6.58
Exchange rate effect
0
-0.01
-0
-0
0
Net change in cash
0.38
1.31
83.2
-17.4
-17.9
-35
3.43
Interest paid
0
0
0
0
0
0
0
Income taxes paid
0
0
0
0
0
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to July 31, 2026; growth uses fiscal years. Valuation uses the share price of $0.44 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-58.7%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-44.0%
Net income / average total assets.
Return on invested capital (ROIC)
-56.7%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Net income growth, 1y
-163.4%
Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y
-186.8%
EPS vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-35.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-22.9%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
37.9%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-15.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-13.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
44.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
14.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
-24.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
42.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
40.3x
Current assets / current liabilities.
Quick ratio
23.2x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
23.2x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.37
Cash from operations / diluted weighted shares.
Book value per share
$2.56
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.17x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.17x
Market cap / tangible book value, when positive.
Earnings yield
-341.0%
Net income / market cap (the inverse of P/E).
What was PharmaCyte Biotech, Inc.'s revenue in fiscal 2026?
PharmaCyte Biotech, Inc. reported revenue of $0.0 for fiscal 2026.
Was PharmaCyte Biotech, Inc. profitable in fiscal 2026?
No. It reported a net loss of $19.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.